Idenix Pharmaceuticals (IDIX) -9.6% after Stifel Nicolaus downgrades shares to Sell from Hold at Stifel Nicolaus, which believes the "significant difference" in potency existing between IDIX's hepatitis C drug and those made by Pharmasset (VRUS) and Inhibitex (INHX) has important implications on how remaining "potential consolidators" strategically view the companies.
Idenix Pharmaceuticals (IDIX) resistance level is $15 and support level is $12.50.
Idenix Pharmaceuticals (IDIX) resistance level is $15 and support level is $12.50.
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/